Table 1.

Clinicopathological characteristics of patients with MBC included in the study (N = 103)

Age, median (range)			71 (31–92)
TNM, n (%)	T	Tis	4 (3.9)
		T1	49 (47.6)
		T2	31 (30.1)
		T3	3 (2.9)
		T4	13 (12.6)
		Unknown	3 (2.9)
	N	N0	80 (77.7)
		N1	18 (17.5)
		N2	0 (0)
		N3	3 (2.9)
		Unknown	2 (1.9)
	M	M0	98 (95.1)
		M1	2 (1.9)
		Unknown	3 (2.9)
Surgery, n (%)	Yes		102 (99)
	No		1 (1.0)
Surgical procedure, n (%)	Bp		2 (2.0)
	Bp + Snb		1 (1.0)
	Bp + ALND		4 (4.0)
	Bt		3 (2.9)
	Bt + Snb		61 (59.8)
	Bt + ALND		29 (28.4)
	Unknown		2 (2.0)
Systemic treatment, n (%)	Neoadjuvant	Yes	12 (11.7)
		No	91 (88.3)
	Adjuvant	Yes	98 (95.1)
		No	5 (4.9)
	Radiotherapy	Yes	13 (12.7)
		No	87 (85.3)
		Unknown	2 (2.0)
Systemic drug treatment, n (%)	Cytotoxic chemotherapy	Yes	31 (30.1)
		No	72 (69.9)
	Endocrine therapy	Yes	95 (92.2)
		No	8 (7.8)
	Anti-HER2 therapy	Yes	5 (4.9)
		No	98 (95.1)
Comorbidity, n (%)	Yes		65 (63.7)
	No		38 (36.3)
		Hypertension	46 (44.7)
		Other malignancy	33 (32)
		Coronary disease	13 (12.6)
		Diabetes	11 (10.7)
		Cerebrovascular disease	9 (8.7)
		Hepatitis	5 (4.9)
		Renal disease	4 (3.9)
		CHF	2 (1.9)
		COPD	2 (1.9)
		Collagen disease	0 (0)
Family history of cancer, n (%)	Yes		51 (49.5)
	No		47 (45.6)
	Unknown		5 (4.9)
		Breast	24 (23.3)
		Colorectal	13 (12.6)
		Gastric	8 (7.8)
		Pancreas	4 (3.9)
		Prostate	1 (1.0)
		Ovary	0 (0)
		Others	23 (22.3)

Bp partial mastectomy, SNB sentinel lymph node biopsy, ALND axillary lymph node dissection, Bt total mastectomy, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, TNM, TNM Classification of Malignant Tumors, 8th edition